Literature DB >> 15161716

The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites.

Daniel Broderick Longley1, Wendy Louise Allen, Ultan McDermott, Timothy Richard Wilson, Tariq Latif, John Boyer, Maria Lynch, Patrick Gerard Johnston.   

Abstract

Fas (CD95/Apo-1) is a member of the tumor necrosis factor receptor family. Receptor binding results in activation of caspase 8, leading to activation of proapoptotic downstream molecules. We found that expression of Fas was up-regulated >10-fold in MCF-7 breast and HCT116 and RKO colon cancer cell lines after treatment with IC(60) doses of 5-fluorouracil (5-FU) and raltitrexed (RTX). Combined treatment with the agonistic Fas antibody CH-11 and either 5-FU or RTX resulted in a highly synergistic induction of apoptosis in these cell lines. Similar results were obtained for another antifolate, Alimta. Induction of thymidylate synthase expression inhibited Fas induction in response to RTX and Alimta, but not in response to 5-FU. Furthermore, thymidylate synthase induction abrogated the synergy between CH-11 and both antifolates but had no effect on the synergistic interaction between 5-FU and CH-11. Inactivation of p53 in MCF-7 and HCT116 cell lines blocked 5-FU- and antifolate-mediated up-regulation of Fas. Furthermore, Fas was not up-regulated in response to 5-FU or antifolates in the p53-mutant H630 colon cancer cell line. Lack of Fas up-regulation in the p53-null and -mutant lines abolished the synergistic interaction between 5-FU and CH-11. Interestingly, synergy was still observed between the antifolates and CH-11 in the p53-null HCT116 and p53-mutant H630 cell lines, although this was significantly reduced compared with the p53 wild-type cell lines. Our results indicate that Fas is an important mediator of apoptosis in response to both 5-FU and antifolates.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161716     DOI: 10.1158/1078-0432.CCR-03-0532

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  12 in total

1.  Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.

Authors:  David S Williams; Dmitri Mouradov; Clare Browne; Michelle Palmieri; Meg J Elliott; Rebecca Nightingale; Catherine G Fang; Rita Li; John M Mariadason; Ian Faragher; Ian T Jones; Leonid Churilov; Niall C Tebbutt; Peter Gibbs; Oliver M Sieber
Journal:  Mod Pathol       Date:  2019-08-30       Impact factor: 7.842

2.  Vanilloids in pancreatic cancer: potential for chemotherapy and pain management.

Authors:  M Hartel; F F di Mola; F Selvaggi; G Mascetta; M N Wente; K Felix; N A Giese; U Hinz; P Di Sebastiano; M W Büchler; H Friess
Journal:  Gut       Date:  2005-09-20       Impact factor: 23.059

3.  Role of caspases in 5-FU and selenium-induced growth inhibition of colorectal cancer cells.

Authors:  Aye Aye Thant; Yanyuan Wu; Jane Lee; Dhruva Kumar Mishra; Heather Garcia; H Phillip Koeffler; Jaydutt V Vadgama
Journal:  Anticancer Res       Date:  2008 Nov-Dec       Impact factor: 2.480

4.  miR-143 overexpression impairs growth of human colon carcinoma xenografts in mice with induction of apoptosis and inhibition of proliferation.

Authors:  Pedro M Borralho; André E S Simões; Sofia E Gomes; Raquel T Lima; Tânia Carvalho; Duarte M S Ferreira; Maria H Vasconcelos; Rui E Castro; Cecília M P Rodrigues
Journal:  PLoS One       Date:  2011-08-25       Impact factor: 3.240

5.  Carcinoembryonic Antigen Expression and Resistance to Radiation and 5-Fluorouracil-Induced Apoptosis and Autophagy.

Authors:  Ebrahim Eftekhar; Hajar Jaberie; Fakhraddin Naghibalhossaini
Journal:  Int J Mol Cell Med       Date:  2016-05-17

6.  Hypoxia increases chemoresistance in human medulloblastoma DAOY cells via hypoxia‑inducible factor 1α‑mediated downregulation of the CYP2B6, CYP3A4 and CYP3A5 enzymes and inhibition of cell proliferation.

Authors:  Jesús Valencia-Cervantes; Sara Huerta-Yepez; Guillermo Aquino-Jarquín; Sara Rodríguez-Enríquez; Daniel Martínez-Fong; José-Antonio Arias-Montaño; Víctor Manuel Dávila-Borja
Journal:  Oncol Rep       Date:  2018-10-12       Impact factor: 3.906

7.  Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.

Authors:  Ten-i Godai; Tetsuji Suda; Nobuhiro Sugano; Kazuhito Tsuchida; Manabu Shiozawa; Hironobu Sekiguchi; Akiko Sekiyama; Mitsuyo Yoshihara; Shoichi Matsukuma; Yuji Sakuma; Eiju Tsuchiya; Yoichi Kameda; Makoto Akaike; Yohei Miyagi
Journal:  BMC Cancer       Date:  2009-12-02       Impact factor: 4.430

Review 8.  The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy.

Authors:  Maurice Michel; Leonard Kaps; Annett Maderer; Peter R Galle; Markus Moehler
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

9.  Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system.

Authors:  Ruolan Han; Yin M Yang; Joerg Dietrich; Anne Luebke; Margot Mayer-Pröschel; Mark Noble
Journal:  J Biol       Date:  2008-04-22

10.  ESE1 expression correlates with neuronal apoptosis in the hippocampus after cerebral ischemia/reperfusion injury.

Authors:  Hai-Long Yu; Liang-Zhu Wang; Ling-Ling Zhang; Bei-Lei Chen; Hui-Juan Zhang; Yu-Ping Li; Guo-Dong Xiao; Ying-Zhu Chen
Journal:  Neural Regen Res       Date:  2019-05       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.